Diaceutics PLC New Vice President of Operations in Asia
April 12 2021 - 1:00AM
RNS Non-Regulatory
TIDMDXRX
Diaceutics PLC
12 April 2021
12 April 2021
Diaceutics PLC
("Diaceutics" or "the Company")
New Vice President of Operations within the Asia Pacific
region
Appointment for Asia Pacific region to expand Diaceutics
portfolio
Diaceutics PLC , ( AIM: DXRX), announces the appointment of
Yvanka Gilliam as Vice President for the Asia Pacific region
(APAC).
In her new role, Yvanka will be responsible for managing
business development and operations within the APAC region with a
core focus on establishing key collaborations and strategic
partnerships to drive growth and revenue. Her role will also
include identifying innovative and creative services and solutions
to help leverage the Company's platform DXRX and increase the
offering.
Yvanka has a strong track record managing the delivery of
real-world insights for evaluation by regulators, payers and
clinicians. Prior to joining Diaceutics, Yvanka worked with Kantar
Health as a Senior Client Partner, Real World Evidence, where she
developed and implemented global business planning strategies and
conducted high-quality research. In recent years, Yvanka has also
worked with IQVIA Asia Pacific in the Real World Insights Division
and as a Senior Medical Science Liaison at AstraZeneca
Pharmaceutical Corporation.
Y vanka holds a doctorate degree in Pharmacy from The University
of Michigan College of Pharmacy in Ann Arbor, a bachelor's degree
in Biology and Chemistry from Grambling University in Louisiana and
an MBA in International Business from Rutgers University Singapore.
Yvanka's work has been published in the Annals of Oncology and the
Journal of Clinical Oncology - an American Society of Clinical
Oncology (ASCO) Journal.
Peter Keeling, Chief Executive Officer of Diaceutics, said:
"Yvanka's appointment will strengthen Diaceutics' credentials as
the market leader in the development and commercialisation of
precision medicine diagnostics. As her 20-plus year career in
pharma has been focused primarily on the Research and Development
of innovative oncology compounds, Yvanka is firmly aligned with
Diaceutics' goal to bridge the gap between diagnostics and
therapeutic decision-making in order to improve testing outcomes
for patients and enable better access to the right drug at the
right time."
Yvanka Gilliam, Diaceutics VP of Operations, APAC, said: "I'm
delighted to join Diaceutics, a Company that I have long admired
for their unwavering commitment to drive better testing and better
treatment for patients. I look forward to broadening Diaceutics'
influence in the APAC region and working alongside a team of driven
and talented individuals. I'm particularly excited to come on board
as the Company's DXRX - The Diagnostic Network(R) platform
continues to gain traction within the industry, as we help get
every patient the treatment they deserve."
About RNS REACH
This is an RNS Reach announcement and the information contained
is not considered to be material or to have a significant impact on
management's expectations of the Group's performance. RNS Reach is
an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on RNS Reach.
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Walbrook PR
Cenkos Securities plc (Nomad & Broker) Tel: +44(0)20 7397
8900
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Tel: +44 (0)7876
741 001
Paul McManus Tel: +44 (0)7980
541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - our Proprietary
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. Diaceutics has
worked on every precision medicine brought to market and provides
solutions to 36 of the world's leading pharmaceutical companies.
DXRX - The Diagnostic Network(R) provides unrivalled access to deep
analysis and insights from the world's largest repository of
diagnostic testing data on one secure platform.
About DXRX - The Diagnostic Network (R)
DXRX is Diaceutics' proprietary diagnostic network for precision
medicine. DXRX is an end-to-end solution for the development and
commercialisation of Precision Medicine diagnostics. The platform
enables a vibrant marketplace where all stakeholders in Precision
Medicine come to find trusted partners and collaborations in a
secure, standardised way. DXRX provides access to a pipeline of
global diagnostic testing data on one secure platform.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFERSVIAIIL
(END) Dow Jones Newswires
April 12, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
